Manila Times Business
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKIIn treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib, a JAK-only inhibitor, in combination with anti-PD-1 antibody enhanced anti-tumor response. SHANGHAI, May 31, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel med
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Solana Unchained Outlines Fixed-Supply Utility Architecture and AI Tool Hub Ahead of Late May Public Allocation Launch
3h ago
IBF champ Jerwin Ancajas’ nephew snares gold in Palaro boxing
4h ago
Espenilla, Cadag deliver breakthrough medals at Asian U20 Championships
4h ago
NCR extends Palarong Pambansa dynasty with 19th straight overall title
4h ago